199 related articles for article (PubMed ID: 29541273)
21. Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/- gammac -/- (RAG-hu) mice.
Berges BK; Akkina SR; Folkvord JM; Connick E; Akkina R
Virology; 2008 Apr; 373(2):342-51. PubMed ID: 18207484
[TBL] [Abstract][Full Text] [Related]
22. Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.
Mandal S; Prathipati PK; Kang G; Zhou Y; Yuan Z; Fan W; Li Q; Destache CJ
AIDS; 2017 Feb; 31(4):469-476. PubMed ID: 28121666
[TBL] [Abstract][Full Text] [Related]
23. Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia.
Claiborne DT; Dudek TE; Maldini CR; Power KA; Ghebremichael M; Seung E; Mellors EF; Vrbanac VD; Krupp K; Bisesi A; Tager AM; Knipe DM; Boutwell CL; Allen TM
J Virol; 2019 Oct; 93(20):. PubMed ID: 31375576
[TBL] [Abstract][Full Text] [Related]
24. The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment.
Seay K; Khajoueinejad N; Zheng JH; Kiser P; Ochsenbauer C; Kappes JC; Herold B; Goldstein H
J Virol; 2015 Sep; 89(18):9559-70. PubMed ID: 26157126
[TBL] [Abstract][Full Text] [Related]
25. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned.
Friend DR; Kiser PF
Antiviral Res; 2013 Sep; 99(3):391-400. PubMed ID: 23845918
[TBL] [Abstract][Full Text] [Related]
26. Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model.
Veselinovic M; Neff CP; Mulder LR; Akkina R
Virology; 2012 Oct; 432(2):505-10. PubMed ID: 22832125
[TBL] [Abstract][Full Text] [Related]
27. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
[TBL] [Abstract][Full Text] [Related]
28. Humanized mouse models of HIV infection.
Denton PW; García JV
AIDS Rev; 2011; 13(3):135-48. PubMed ID: 21799532
[TBL] [Abstract][Full Text] [Related]
29. Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery system.
Machado A; Cunha-Reis C; Araújo F; Nunes R; Seabra V; Ferreira D; das Neves J; Sarmento B
Acta Biomater; 2016 Oct; 44():332-40. PubMed ID: 27544812
[TBL] [Abstract][Full Text] [Related]
30. The lantibiotic peptide labyrinthopeptin A1 demonstrates broad anti-HIV and anti-HSV activity with potential for microbicidal applications.
Férir G; Petrova MI; Andrei G; Huskens D; Hoorelbeke B; Snoeck R; Vanderleyden J; Balzarini J; Bartoschek S; Brönstrup M; Süssmuth RD; Schols D
PLoS One; 2013; 8(5):e64010. PubMed ID: 23724015
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus.
Bobardt MD; Cheng G; de Witte L; Selvarajah S; Chatterji U; Sanders-Beer BE; Geijtenbeek TB; Chisari FV; Gallay PA
Proc Natl Acad Sci U S A; 2008 Apr; 105(14):5525-30. PubMed ID: 18378908
[TBL] [Abstract][Full Text] [Related]
32. Animal models of antiretroviral prophylaxis for HIV prevention.
García-Lerma JG; Heneine W
Curr Opin HIV AIDS; 2012 Nov; 7(6):505-13. PubMed ID: 22964889
[TBL] [Abstract][Full Text] [Related]
33. Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS.
Gupta SK; Nutan
HIV AIDS (Auckl); 2013 Oct; 5():295-307. PubMed ID: 24174883
[TBL] [Abstract][Full Text] [Related]
34. Prevention of vaginal and rectal herpes simplex virus type 2 transmission in mice: mechanism of antiviral action.
Ceña-Diez R; Vacas-Córdoba E; García-Broncano P; de la Mata FJ; Gómez R; Maly M; Muñoz-Fernández MÁ
Int J Nanomedicine; 2016; 11():2147-62. PubMed ID: 27274240
[TBL] [Abstract][Full Text] [Related]
35. Prophylactic contraceptives for HIV/AIDS.
Uckun FM; D'Cruz OJ
Hum Reprod Update; 1999; 5(5):506-14. PubMed ID: 10582788
[TBL] [Abstract][Full Text] [Related]
36. Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.
Le Grand R; Dereuddre-Bosquet N; Dispinseri S; Gosse L; Desjardins D; Shen X; Tolazzi M; Ochsenbauer C; Saidi H; Tomaras G; Prague M; Barnett SW; Thiebaut R; Cope A; Scarlatti G; Shattock RJ
J Virol; 2016 Jun; 90(11):5315-5328. PubMed ID: 27009957
[TBL] [Abstract][Full Text] [Related]
37. Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission.
Kovarova M; Council OD; Date AA; Long JM; Nochi T; Belshan M; Shibata A; Vincent H; Baker CE; Thayer WO; Kraus G; Lachaud-Durand S; Williams P; Destache CJ; Garcia JV
PLoS Pathog; 2015 Aug; 11(8):e1005075. PubMed ID: 26271040
[TBL] [Abstract][Full Text] [Related]
38. A Small-Molecule CD4-Mimetic Compound Protects Bone Marrow-Liver-Thymus Humanized Mice From HIV-1 Infection.
Princiotto AM; Vrbanac VD; Melillo B; Park J; Tager AM; Smith AB; Sodroski J; Madani N
J Infect Dis; 2018 Jul; 218(3):471-475. PubMed ID: 29617845
[TBL] [Abstract][Full Text] [Related]
39. Combining biomedical preventions for HIV: Vaccines with pre-exposure prophylaxis, microbicides or other HIV preventions.
McNicholl JM
Hum Vaccin Immunother; 2016 Dec; 12(12):3202-3211. PubMed ID: 27679928
[TBL] [Abstract][Full Text] [Related]
40. Rectal and vaginal immunization with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses.
Kato H; Bukawa H; Hagiwara E; Xin KQ; Hamajima K; Kawamoto S; Sugiyama M; Sugiyama M; Noda E; Nishizaki M; Okuda K
Vaccine; 2000 Jan; 18(13):1151-60. PubMed ID: 10649615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
